Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Morgan Stanley Maintains Overweight on PACCAR

Morgan Stanley Maintains Overweight on PACCAR

Morgan Stanley analyst Dillon Cumming maintains PACCAR (NASDAQ:PCAR) with a Overweight.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Morgan Stanley analyst Dillon Cumming maintains PACCAR (NASDAQ:PCAR) with a Overweight.

News

Better Therapeutics Amends Debt Facility, Likely to Improve its Financial Position by $5M through Q1 of 2024

By Benzinga Newsdesk

November 28, 8:50 AM

Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's

BTTX

Analyst Ratings

Analyst Expectations For Crane’s Future

By Benzinga Insights

April 24, 3:00 PM

In the preceding three months, 4 analysts have released ratings for Crane (NYSE:CR), presenting a wide array of…

Deutsche Bank Maintains Hold on Darden Restaurants, Lowers Price Target to $129

By Benzinga Newsdesk

September 23, 9:58 AM

Deutsche Bank analyst Brian Mullan maintains Darden Restaurants (NYSE:DRI) with a Hold and lowers the price target from $131 to $129.

DRI

Raymond James Maintains Outperform on Dyne Therapeutics, Raises Price Target to $16

By Benzinga Newsdesk

November 4, 5:22 AM

Raymond James analyst Steven Seedhouse maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $15 to $16.

DYN

Morgan Stanley Maintains Overweight on PACCAR

Related Posts

Better Therapeutics Amends Debt Facility, Likely to Improve its Financial Position by $5M through Q1 of 2024

Analyst Expectations For Crane’s Future

Deutsche Bank Maintains Hold on Darden Restaurants, Lowers Price Target to $129

Raymond James Maintains Outperform on Dyne Therapeutics, Raises Price Target to $16